Asset Details
Do you wish to reserve the book?
Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche
Do you wish to request the book?
Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche
2013
Overview
The sub-population of tumor cells termed ‘cancer stem cells’ (CSCs) possess the capability to generate tumors, undergo epithelial–mesenchymal transition (EMT) and are implicated in metastasis, making treatments to specifically target CSCs an attractive therapeutic strategy. Tumor hypoxia plays a key role in regulating EMT and cancer stem cell function. Carbonic anhydrase IX (CAIX) is a hypoxia-inducible protein that regulates cellular pH to promote cancer cell survival and invasion in hypoxic microenvironments and is a biomarker of poor prognosis for breast cancer metastasis and survival. Here, we demonstrate that inhibition of CAIX expression or activity with novel small-molecule inhibitors in breast cancer cell lines, or in primary metastatic breast cancer cells, results in the inhibition of breast CSC expansion in hypoxia. We identify the mTORC1 axis as a critical pathway downstream of CAIX in the regulation of cancer stem cell function. CAIX is also required for expression of EMT markers and regulators, as well as drivers of ‘stemness’, such as Notch1 and Jagged1 in isolated CSCs. In addition, treatment of mice bearing orthotopic breast tumors with CAIX-specific small-molecule inhibitors results in significant depletion of CSCs within these tumors. Furthermore, combination treatment with paclitaxel results in enhanced tumor growth delay and eradication of lung metastases. These data demonstrate that CAIX is a critical mediator of the expansion of breast CSCs in hypoxic niches by sustaining the mesenchymal and ‘stemness’ phenotypes of these cells, making CAIX an important therapeutic target for selectively depleting breast CSCs.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Publishing Group [1987-....]
Subject
/ Animals
/ Antigens, Neoplasm - metabolism
/ Antineoplastic Agents - pharmacology
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - enzymology
/ Breast Neoplasms - pathology
/ Carbonic Anhydrase Inhibitors - pharmacology
/ Carbonic Anhydrases - metabolism
/ Female
/ Humans
/ Hypoxia
/ Lung Neoplasms - prevention & control
/ Medicine
/ Mice
/ Neoplastic Stem Cells - drug effects
/ Neoplastic Stem Cells - enzymology
/ Oncology
/ Phenylurea Compounds - pharmacology
/ Spheroids, Cellular - enzymology
/ Tumors
